GlobeNewswire by notified

Codex Labs Introduces Integrative Medical Advisory Board

Share

San Jose, CA, May 25, 2023 (GLOBE NEWSWIRE) -- Codex Labs, a Silicon Valley bio-skintech company, announced an expanded medical advisory board (MAB) to support its focus on integrative skin-gut-brain solutions. 

The Chairman of the MAB is Dr. Raja Sivamani, MD MS AP, is an integrative dermatologist, bioengineer, and Ayurvedic practitioner.  He is the Director of Clinical Dermatology Research at the University of California, Davis as well as the Co-Director of the Microbiome Research Initiative at California State University, Sacramento.

The MAB comprises dermatology experts:

  • Dr. Peter Lio, MD FAAD, is a Clinical Assistant Professor of Dermatology & Pediatrics at Northwestern University.  He is the founding director of the Chicago Integrative Eczema Center and a board member of the National Eczema Association.
  • Dr. Anat Lebow, MD, specializes in medical and cosmetic dermatology.  Her expertise includes inflammatory disorders such as psoriasis, atopic/eczematous dermatitis, skin cancers, and sun-damaged or aging skin.
  • Dr. Apple Bodemer, MD, is an Associate Professor of Dermatology at the University of Wisconsin.  She is also board certified in Integrative Medicine and Lifestyle Medicine, and is active on the American Board of Integrative Medicine.
  • Dr. Tara Rao, MD, specializes diagnosing and managing skin cancer, including dermoscopy and surgical excisions. She also has an interest in treating pigmentary skin disorders such as vitiligo and melasma. 
  • Dr. Jennifer Sawaya, MD, is a board-certified dermatologist as well as cosmetic and laser dermatologic surgeon.  She specializes in cosmetic injectables and energy-based devices. 

The MAB also comprises functional nutrition experts:

  • Paula Simpson, RNCP, B.Sc., is a biochemist, herbalist, functional nutrition specialist, and a recognized nutricosmetics and microbiome innovator. She is a media expert and published author.
  • Dr. Jessica Maloh, ND, is a naturopathic doctor whose research interests and clinical practice focus on the role of nutrition, microbiome, mindfulness, and quality of life in various dermatological conditions.

About Codex Labs

Based in Silicon Valley and led by scientist Dr. Barbara Paldus, Codex Labs is committed to creating  highly effective, clinically proven, microbiome-supporting skin-gut-brain integrative solutions  that contain potent, biotech-derived plant-based actives. Our products are focused on restoring/protecting the skin barrier, managing inflammation, and addressing skin conditions associated with aging, acne, eczema and psoriasis. Our free DermSCORE self-assessment app offers consumers a data-driven, derm-approved approach for managing acne.  The brand has been heralded by dermatologists for creating a new breed of effective, vegan, cruelty-free and sustainable dermo-cosmetic solutions.  

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons3.5.2024 19:48:16 CEST | Press release

Bagsværd, Denmark, 3 May 2024 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have reported the transactions to Novo Nordisk and have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company’s board members, executives and their associated persons. Please find below a statement of such trading in shares issued by Novo Nordisk. Details of the person discharging managerial responsibilities/person closely associated a)Name of the Board member/Executive/Associated PersonMaziar Mike Doustdar2 Reason for the notificationa)Position/statusExecutive Vice Presidentb)Initial notification/AmendmentInitial notification3 Details of the issuera)NameNovo Nordisk A/Sb)LEI549300DAQ1CVT6CXN342

Subsea 7 S.A. notification of major holding3.5.2024 18:32:01 CEST | Press release

Luxembourg –3 May 2024 – Subsea 7 S.A. (Oslo Børs: SUBC, ADR: SUBCY) today announced that, on 3 May 2024, Barclays Capital Securities Limited1 informed the Company that it had breached thresholds provided for by Luxembourg’s Transparency Law of 11 January 2008 on transparency requirements for issuers of securities as amended (the “Transparency Law”) as follows: On 30 April 2024 the total number of voting rights in the Company according to Article 8 and 9 of the Transparency Law attached to shares was 1,044,272 On 30 April 2024 the total number of voting rights in the Company attached to financial instruments with similar economic effect according to Article 12 (1) (a) of the Transparency Law (right to recall) was 13,906,019On 30 April 2024 the total number of voting rights in the Company attached to financial instruments with similar economic effect according to Article 12 (1) (b) of the Transparency Law (swaps) was 499,740 When combined, the above positions equate to 5.07% of voting r

NGS Group AB: NGS Group offentliggör utfall i riktad emission om 16,1 MSEK3.5.2024 18:00:00 CEST | Pressemelding

NGS Group AB:s (publ) (”NGS Group” eller ”Bolaget”) nyemission av aktier riktad till strategiska investerare om cirka 16,1 MSEK, före emissionskostnader (den ”Riktade Emissionen”) som beslutades av styrelsen den 29 februari 2024 och godkändes av den extra bolagsstämman den 26 mars 2024, har tecknats med totalt 4 962 577 aktier. Genom den Riktade Emissionen tillförs Bolaget cirka 16,1 MSEK, före avdrag för emissionskostnader. Utfall i den Riktade Emissionen Hugo Lewné och Nils Sjögren har tecknat och tilldelats totalt 4 962 577 aktier motsvarande cirka 16,1 MSEK i den Riktade Emissionen. Storleken på den Riktade Emissionen styrdes av teckningsgraden i den nyemission av aktier med företrädesrätt för befintliga aktieägare om ca 35,2 MSEK, före emissionskostnader (”Företrädesemissionen” och tillsammans med den Riktade Emissionen ”Emissionerna”) vari slutligt utfall offentliggjordes den 29 april 2024. Då Företrädesemissionen övertecknades innebär det att den Riktade Emissionens omfattning ä

Bulletin from BTS Group AB's Annual General Meeting3.5.2024 17:34:40 CEST | Press release

Stockholm May 3, 2024 The Annual General Meeting approved the proposed dividend to shareholders of SEK 5,70 per share, divided into two payment occasions of SEK 2,85 each. The record date for the first payment of SEK 2,85 was determined to Tuesday May 7, 2024 and for the second payment of SEK 2,85 was determined to Wednesday November 13, 2024. The first payment is expected to be made on Monday May 13, 2024 and the second payment is expected to be made on Monday November 18, 2024. The Annual General Meeting discharged the members of the Board of Directors and the CEO from liability for the financial year 2023 and approved the remuneration report for 2023 prepared by the Board of Directors. The Annual General Meeting approved the remuneration to board members to a total of SEK 1,735,000, of which SEK 525,000 to the Chairman and SEK 235,000 to each of the other board members, and SEK 60,000 to the Deputy Board member. A total fee of SEK 225,000 shall be paid for committee work. Mariana Bu

Kommuniké från BTS Group ABs årsstämma3.5.2024 17:34:40 CEST | Pressemelding

Stockholm 3 maj 2024 Årsstämman fastställde föreslagen utdelning till aktieägarna om 5,70 kronor per aktie, uppdelat på två utbetalningstillfällen om vardera 2,85 SEK. Som avstämningsdag för den första utbetalningen om 2,85 SEK fastställdes tisdagen den 7 maj 2024 och för den andra utbetalningen om 2,85 SEK fastställdes onsdagen den 13 november 2024. Den första utbetalningen beräknas ske måndagen den 13 maj 2024 och den andra utbetalningen beräknas ske måndagen den 18 november 2024. Årsstämman beviljade styrelseledamöterna och verkställande direktören ansvarsfrihet för verksamhetsåret 2023 samt godkände den av styrelsen upprättade ersättningsrapporten för 2023. Årsstämman fastställde arvodet till styrelseledamöter till totalt 1 735 000 kronor, varav 525 000 kronor till ordföranden och 235 000 kronor till respektive övrig styrelseledamot, samt 60 000 kronor till styrelsesuppleanten. För utskottsarbete skall ett totalt arvode om 225 000 kronor utgå. Mariana Burenstam Linder, Stefan Garde

HiddenA line styled icon from Orion Icon Library.Eye